This content is machine translated Non-resectable BRAF-mutated melanoma Update COLUMBUS study: BRAF/MEK inhibition has long-lasting effect For almost two years, an effective therapeutic option has been available for patients with non-resectable or metastatic BRAFV600-mutated melanoma with the combination of encorafenib plus binimetinib. An analysis of the…
